Kari A. Mergenhagen, PharmD, BCPS, BCIDP, discusses the potential of doxycycline in reducing C difficile infections among hospitalized patients with pneumonia. This interview delves into doxycycline's influence on patients with a prior C difficile history, demographic generalizability, exclusion criteria, and concerns regarding antibiotic resistance.
New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks which correlated with improved quality-of-life scores.
Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.